Imunofan suppositories 90mkg, No. 5

Rectally. Single dose and daily dose - 100 mcg (1 suppository).
In the treatment of cancer patients in the scheme of radical combined treatment (chemo-radiation therapy and surgery):

• once, daily, a course of treatment of 8-10 suppositories before chemo-radiation therapy and surgery, followed by continuation of the course throughout the entire period of treatment.

In patients with a widespread tumor process (stage III - IV) of various localization in the form of complex or symptomatic therapy:

• once, daily, the course of treatment is 8-10 suppositories, with a break of 15-20 days and repetition of courses during the entire period of subsequent treatment.

In children with malignant diseases of the hematopoietic and lymphoid tissue:

• Once a day, daily, a course of treatment is 10-20 suppositories. The appointment of the drug should be carried out during the entire course of chemotherapy and radiation therapy and after the end of the course to prevent the development of toxicosis.

In the complex therapy of children with papilomatosis of the larynx and oropharynx:

• Once a day, daily, a course of treatment is 10 suppositories.

With opportunistic infections (cytomegalovirus and herpes infection, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis):

• Once a day, daily, the course of treatment is 15 - 20 suppositories.

In the complex therapy of HIV infection:

• Once a day, daily, the course of treatment is 15 - 20 suppositories. If necessary, repeated courses should be carried out in 2-4 weeks.

For chronic viral hepatitis and chronic brucellosis:

• Once a day, every day, the course of treatment is 15 - 20 suppositories; to prevent relapse, repeated courses should be carried out in 2 - 3 months.

With diphtheria:

• Once a day, daily, the course of treatment is 8-10 suppositories. In case of diphtheria bacterial carrier - 1 time in 3 days - 3-5 suppositories.

In the treatment of III-IV degree burns with symptoms of toxemia, septicotoxemia, in surgical patients with septic endocarditis, long-term non-healing wounds of the extremities, purulent-septic complications:

• Once a day, daily, the course of treatment is 7-10 suppositories, if necessary, the course of the drug should be continued up to 20 suppositories.

With broncho-obstructive syndrome, cholecystopancreatitis, rheumatoid arthritis:

• Once every 3 days, the course of treatment is 8-10 suppositories, if necessary, the course should be continued up to 20 suppositories with the same interval.

When treating psoriasis:

• Once a day, daily, the course of treatment is 15 - 20 suppositories.

In adults, in the vaccine prophylaxis scheme, once a day of vaccination.

Active ingredient: Imunofan - 100 mcg.

Excipients: purified water, glycine, solid fat, tween 80.

• Hypersensitivity

• pregnancy complicated by Rh-conflict,

• children's age up to 2 years.

Pharmacological properties
The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. The pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the oxidative-antioxidant reaction of the body and inhibition of multidrug resistance mediated by proteins of the transmembrane transport pump of the cell.

The effect of the drug begins to develop within 2 to 3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the fast phase (duration - up to 2-3 days), the detoxification effect is manifested first of all - the antioxidant defense of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol levels and the production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.

During the middle phase (starts after 2-3 days, duration - up to 7-10 days), there is an increase in the reactions of phagocytosis and death of intracellular bacteria and viruses. During the slow phase (it begins to develop on days 7-10, duration up to 4 months), the immunoregulatory effect of Imunofan is manifested - the restoration of disturbed parameters of cellular and humoral immunity. During this period, there is a normalization of the immuno-regulatory index, an increase in the production of specific antibodies is noted. The effect of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of some therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reaginic antibodies of the IgE class and does not enhance the immediate hypersensitivity reaction;Imunofan stimulates the formation of IgA in congenital insufficiency.

Imunofan effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the action of cytostatic drugs.

Side effect.
Allergic reactions to the components of the drug.

Interaction with other medicinal products.
The action of Imunofan does not depend on the production of PGE2 and the administration of the drug is possible in combination with anti-inflammatory (steroid and non-steroidal) drugs.